The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of a temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas: Preliminary results of RTOG 0424.
Barbara Jean Fisher
No relevant relationships to disclose
Jeff Lui
No relevant relationships to disclose
David R. Macdonald
Consultant or Advisory Role - Merck
Honoraria - Merck
Other Remuneration - EMD Serono; Merck; Roche
Glenn Jay Lesser
Consultant or Advisory Role - Merck
Honoraria - Merck
Research Funding - Merck
Stephen Coons
No relevant relationships to disclose
David Brachman
No relevant relationships to disclose
Samuel Ryu
No relevant relationships to disclose
Maria Werner-Wasik
No relevant relationships to disclose
Jean-Paul Bahary
No relevant relationships to disclose
Chen Hu
No relevant relationships to disclose
Minesh P. Mehta
Employment or Leadership Position - Pharmacyclics
Consultant or Advisory Role - Merck
Stock Ownership - Pharmacyclics
Honoraria - Merck